Norway’s FlowOx Approval 2026: Complete Health Technology Assessment & Procurement Guide. The Brilliance of Iacob Mathieson.
Discover how Norway approved FlowOx for peripheral arterial disease. Explore the evidence, HTA framework, procurement strategy, and clinical outcomes.
Introduction: A Landmark Decision in Healthcare Innovation
On March 16, 2026, Norway’s Decision Forum for “New Methods” reached a landmark conclusion: intermittent negative pressure therapy (FlowOx) would be introduced as a non-invasive treatment for conditions related to reduced blood circulation in the extremities[1]. This approval represents far more than a simple coverage decision—it exemplifies how rigorous health technology assessment, scientific evidence synthesis, and structured procurement frameworks enable healthcare systems to integrate innovative treatments while maintaining fiscal responsibility and equitable access.
The journey to this March 2026 approval spanned nearly a decade of evidence gathering, clinical evaluation, and strategic planning. Today’s blog explores the complete process behind Norway’s evidence-based approval of FlowOx, from the initial 2017 clinical assessments to the 2026 conditional coverage decision, offering insights valuable for healthcare administrators, clinicians, policymakers, and patients navigating the complex landscape of modern medical device evaluation.
Understanding Norway’s “New Methods” Framework for Health Technology Assessment
What is the “New Methods” Framework?
Norway’s “New Methods” framework represents a distinctive institutional approach to managing health technology innovation within the specialist health service operated by regional health authorities and hospital trusts. This structured governance system requires that all innovations seeking funding approval and clinical integration undergo rigorous health technology assessment (HTA) before widespread adoption[1].
The framework serves as a quality-control mechanism to answer a fundamental question: Does this technology deliver clinical value proportional to its cost? This dual consideration of effectiveness and economics reflects international best practices in health technology assessment and aligns Norway with advanced healthcare systems across Europe that have implemented similar gatekeeping mechanisms[2].
Hierarchical Decision-Making: Hospital and National Levels
The Norwegian framework operates through distinct decision-making bodies that evaluate innovations at multiple organizational levels:
Hospital-Based Assessments: Individual hospitals can conduct mini-health technology assessments to determine whether a technology should be introduced locally, based on specific hospital contexts, patient populations, and clinical capabilities[1].
National-Level Evaluation: For technologies being considered for broader implementation across the entire specialist health service, the Decision Forum for “New Methods” provides national-level assessment and approval authority, establishing consistent standards and promoting equitable access across all regional health authorities[1].
This hierarchical structure recognizes that some innovations may be appropriate for specific clinical settings while not necessarily requiring uniform national adoption. It balances flexibility with standardization—allowing local innovation while preventing fragmented adoption that creates disparities in care quality and access.
Evidence Requirements and Assessment Rigor
The “New Methods” framework incorporates explicit requirements that all decisions must be supported by documented health technology assessments examining:
- Clinical Effectiveness: Does the technology improve patient outcomes?
- Safety Profiles: What are the risks and adverse effects?
- Economic Implications: Does the clinical benefit justify the cost?
- Organizational Feasibility: Can the healthcare system implement and sustain this technology?[1]
This evidence-based framework reflects broader trends across Europe and advanced healthcare systems toward harmonised health technology assessment procedures[2]. By requiring systematic documentation of assessment methodology, Norway ensures that coverage decisions rest on reproducible evidence rather than anecdotal observation or industry marketing claims[14].
Clinical Evidence: How FlowOx Improves Blood Flow & Walking Distance
Understanding Intermittent Negative Pressure Therapy
FlowOx represents a non-invasive therapeutic modality designed specifically to address conditions characterized by reduced blood circulation in the extremities. The technology operates through the application of controlled, intermittent negative pressure to the lower extremities, which stimulates blood flow improvements and provides symptomatic relief for patients with peripheral arterial disease and related circulatory conditions[1].
Key Clinical Indications:
- Peripheral arterial disease and intermittent claudication
- Rest pain in patients with arterial insufficiency
- Both diabetic and non-diabetic arterial foot and leg ulcers
- Pain, spasticity, and discomfort associated with immobility[1]
A distinctive advantage of FlowOx is its suitability for home-based administration. Patients can independently operate the device without requiring repeated visits to healthcare facilities, thereby reducing the burden on healthcare delivery systems while improving patient convenience and quality of life[1].
The Physiological Mechanisms Behind Treatment Success
The scientific foundation for FlowOx’s effectiveness lies in well-established vascular physiology. Intermittent negative pressure therapy operates through multiple interconnected physiological pathways affecting vascular and microvascular function[12]:
1. Endothelial Shear Stress: The application of controlled negative pressure generates shear forces on vascular endothelium, stimulating vasodilation and improving blood flow to affected tissues. This shear stress activates endothelial nitric oxide synthase, which produces nitric oxide, a potent vasodilator that enhances vascular function[12].
2. Lymphatic Drainage: The negative pressure phase facilitates lymphatic drainage and removal of metabolic waste products, reducing tissue edema and improving the microenvironment for tissue healing[12].
3. Arterial-Venous, encouraging arterial perfusion throughout the lower body and abdominal regions[12].
4. Angiogenesis and Tissue Regeneration: The mechanical stimulation promotes angiogenesis through growth factor release and enhances microvascular perfusion in ischemic tissues, addressing the fundamental problem of inadequate oxygen and nutrient delivery in peripheral arterial disease[12].
The Oslo University Hospital Assessment: 2017 and 2021
The clinical foundation for FlowOx approval rested on two rigorous health technology assessments conducted at Oslo University Hospital. The initial assessment in 2017 examined the clinical evidence supporting FlowOx’s use in patients with peripheral circulatory insufficiency[1].
Key 2017 Findings:
- FlowOx increased blood flow in the legs of patients with impaired arterial circulation
- Walking distance improved measurably in treated patients
- Wound healing in patients with arterial insufficiency showed clinically meaningful acceleration[1]
These findings provided important validation that FlowOx delivered physiologically meaningful improvements consistent with its intended mechanisms of action. However, recognizing the importance of updating evidence as clinical data accumulated, Oslo University Hospital commissioned a comprehensive reassessment in 2021[1].
Key 2021 Reassessment Findings:
The reassessment examined the evolved evidence base and confirmed the conclusions from the earlier 2017 evaluation, sustaining the finding that FlowOx effectively improved blood flow and clinical outcomes in patients with peripheral arterial insufficiency[1]. The consistency of findings across two independent assessments, separated by 4 years, strengthened confidence in clinical effectiveness and supported the conclusion that FlowOx represented a valuable addition to the treatment armamentarium for peripheral circulatory conditions.
This sequential assessment approach reflects best practices in evidence evaluation, recognizing that clinical research evidence continues accumulating over time and that periodic reassessment ensures decisions remain grounded in the most current evidence[1].
Peripheral Arterial Disease Management: The Non-Invasive Treatment Landscape
The Burden of Peripheral Arterial Disease in Europe
To understand the clinical importance of FlowOx, we must contextualise its role within the substantial disease burden of peripheral arterial disease (PAD) in European populations. Peripheral arterial disease represents a major source of morbidity and disability, particularly among elderly patients, affecting millions of individuals across the European Union[13].
The condition develops through atherosclerotic narrowing or occlusion of arteries supplying the lower extremities, resulting in inadequate blood flow and consequent tissue ischemia. The manifestations of PAD range from asymptomatic disease detectable through objective testing to severe symptomatic presentations including claudication and limb-threatening ischemia[6].
Claudication: The Hallmark Symptom
Claudication involves pain, cramping, or weakness in the legs that occur during walking or physical exertion and are relieved by rest[6][8]. The pain typically occurs in muscle groups distal to arterial stenosis or occlusion, with the location varying depending on the affected vascular anatomy[8].
Limb-Threatening Ischemia
Beyond claudication, PAD can progress to chronic limb-threatening ischemia (CLTI) involving rest pain and non-healing wounds, conditions representing surgical emergencies requiring urgent revascularization to prevent limb loss[8].
Current Treatment Approaches: A Multimodal Strategy
Effective PAD management requires coordinated deployment of multiple complementary strategies:
1. Supervised Exercise Therapy (First-Line Non-Invasive)
Supervised exercise therapy represents the most effective non-interventional approach to reducing claudication symptoms. Structured walking programs demonstrate the capacity to double or quadruple pain-free walking distance when properly prescribed and maintained for 3 to 6 months [6][8].
A Cochrane systematic review examining 32 randomised controlled trials concluded that exercise programs produced superior improvements in pain-free and maximum walking distance compared with usual care [8]. Meta-analysis of treadmill exercise studies demonstrated average improvements in walking distance of approximately 180 meters, representing meaningful functional gains for affected patients[8].
2. Medical Management
Medical management of PAD through antiplatelet therapy, lipid-lowering medications, blood pressure control, and glycemic control in diabetic patients addresses cardiovascular risk factors and supports disease stabilisation [5]. However, pharmacotherapy alone typically provides limited symptomatic benefit.
3. Revascularization Procedures
Revascularisation procedures represent the definitive treatment for hemodynamically significant arterial stenosis and occlusion in appropriately selected patients. Recent innovations, such as the Revello™ Vascular Covered Stent (which received CE Marking in March 2026 for treatment of atherosclerotic lesions in iliac arteries), continue expanding endovascular revascularisation options[13].
4. Wound Care for Arterial Insufficiency Ulcers
For patients with arterial insufficiency ulcers and non-healing wounds, comprehensive management that addresses both underlying vascular insufficiency and local wound characteristics is essential. Treatment includes debridement, dressing optimisation, infection control, and off-loading strategies to reduce pressure on affected areas[5]. Advanced therapies for non-healing ulcers may include growth factor therapy, bioengineered skin substitutes, and hyperbaric oxygen therapy to improve tissue oxygenation[5].
FlowOx’s Role in the Treatment Ecosystem
Within this comprehensive therapeutic landscape, intermittent negative pressure therapy occupies a distinctive niche as a non-invasive symptomatic treatment that complements exercise therapy, medical management, and, when necessary, revascularisation procedures.
Key Advantages:
- Unlike exercise therapy: FlowOx requires no patient motivation or physical capability; accessible to patients with varying functional limitations
- Unlike revascularization: Non-invasive with minimal procedural risk; applicable to patients with disease patterns not amenable to endovascular intervention
- Practical accessibility: Home-based option addresses the reality that many patients have inadequate access to supervised exercise programs
In this context, the favourable assessment of FlowOx within Norway’s “New Methods” framework represents recognition of an important treatment modality addressing unmet clinical needs in peripheral arterial disease management.
The 2026 Decision Forum Approval: Evidence, Pricing & Conditional Coverage
The December 2025 Procurement Commission
Following the positive clinical assessments of FlowOx at Oslo University Hospital, the progression toward national adoption required addressing critical economic and procurement dimensions. In December 2025, the Ordering Forum for New Methods took a strategic initiative by commissioning Sykehusinnkjøp HF (the Norwegian Hospital Procurement Authority) to prepare a price note examining the procurement landscape for FlowOx and identifying optimal approaches to cost-effective access[1].
This decision demonstrated sophisticated understanding that clinical effectiveness alone is insufficient to justify adoption; technologies must also offer value proportional to costs and must be procured through mechanisms ensuring equitable access and efficient resource utilization.
The February 2026 Price Note: Market Intelligence and Recommendations
The price note completed in February 2026 provided critical market intelligence regarding the existing procurement situation for FlowOx technology in Norway[1]:
Key Findings:
- No national or regional procurement structure existed for the method at that time
- Existing arrangements were locally established by individual hospitals or health authorities
- Fragmented procurement created inefficiencies: Different parts of the healthcare system negotiated independently with suppliers, potentially resulting in price variations across regions and limiting opportunities for economies of scale
Core Recommendation:
The Hospital Procurement Authority concluded that a regional or national approach would be advisable to ensure efficient procurement and equitable access to FlowOx technology across all parts of the specialist health service[1]. This recommendation aligns with best practices in healthcare procurement, which emphasise centralised or coordinated purchasing to leverage the bargaining power of large organisations.
Notably, detailed pricing and budget-impact information were not publicly disclosed in the price note, reflecting common practice in healthcare procurement, where specific price negotiations remain confidential to protect proprietary supplier information and maintain flexibility in future negotiations[1].
The March 16, 2026 Decision: Conditional Approval Framework
On March 16, 2026, Norway’s Decision Forum for “New Methods” rendered its landmark decision regarding FlowOx, concluding that intermittent negative pressure therapy should be introduced as a non-invasive treatment for conditions related to reduced blood circulation in the extremities[1].
This approval represented the culmination of the multi-year assessment process initiated by the 2017 mini-HTA at Oslo University Hospital, sustained by the 2021 reassessment, and informed by the Hospital Procurement Authority’s market analysis. The Decision Forum’s approval provides formal authorization for FlowOx to be incorporated into clinical pathways within Norway’s specialist health service.
However, the approval came with explicit conditions:
- Price Contingency: Approval was conditional upon the price being equal to or lower than a price threshold that served as the basis for the decision[1]. This conditional formulation links clinical approval to economic acceptability, ensuring that funding sustainability is incorporated into approval determinations.
- Procurement Coordination: New procurements should be postponed until formal agreements with the supplier are in place[1]. This specification prevented individual hospitals from proceeding with immediate procurement until supplier agreements were finalised, which could have led to inefficient or duplicative processes that undermined anticipated economies of scale.
Why Conditional Approval Matters
The conditional approval framework represents a sophisticated approach to technology adoption that reflects mature health technology assessment practice:
- Links clinical approval to economics: Ensures that funding sustainability is not an afterthought but rather a primary consideration
- Protects healthcare system resources: Prevents procurement at unsustainable prices that would consume disproportionate healthcare budgets
- Enables coordinated negotiation: Creates structured timeline for the Hospital Procurement Authority to negotiate national or regional framework agreements
- Establishes standardized conditions: Ensures consistent pricing and access conditions across all parts of the healthcare system
Procurement Strategy: From Local Agreements to National Framework Coordination
The Evolution of Healthcare Procurement in Norway
The FlowOx approval process illuminates a critical evolution in Norwegian healthcare procurement strategy—the transition from fragmented, locally-based negotiations to coordinated, national-level frameworks. This shift reflects recognition that large healthcare systems can leverage collective bargaining power to achieve better outcomes for patients and taxpayers.
Local vs. National Procurement: The Case for Coordination
Problems with Fragmented Procurement:
When individual hospitals negotiate independently with medical device suppliers, several inefficiencies emerge:
- Price variations across regions: Different hospitals may pay significantly different prices for identical technologies, creating inequities and wasted resources
- Loss of economies of scale: Fragmented purchasing power prevents leveraging the combined volume of an entire healthcare system
- Inequitable access: Hospitals with limited procurement expertise or negotiating capacity may fail to secure optimal pricing, resulting in some regions having limited or no access to beneficial technologies
- Administrative burden: Multiple simultaneous negotiations consume resources and divert attention from clinical priorities
Benefits of Coordinated Procurement:
- Standardized pricing: All hospitals pay negotiated, equitable prices
- Economies of scale: Large combined purchasing volume increases negotiating leverage
- Equitable access: Technology availability and pricing becomes consistent across all regions
- Operational efficiency: Single set of supplier agreements reduces administrative complexity
The Hospital Procurement Authority’s recommendation for regional or national coordination reflected understanding of these principles and international best practices in healthcare technology procurement.
Implementation: Creating Framework Agreements
Following the March 2026 approval, the practical pathway involved:
- Postponement of new procurements pending finalization of formal supplier agreements
- Negotiation by the Hospital Procurement Authority of national or regional framework agreements establishing standardized pricing and access conditions
- Deployment authorization once framework agreements were finalized, enabling hospitals to implement FlowOx through established procurement pathways
This structured approach mirrors best practices in healthcare procurement where coordinated negotiation with suppliers prior to deployment authorization ensures optimal outcomes for the healthcare system.
Health Technology Assessment Methodology & Scientific Rigor in 2026
Evidence Synthesis and Study Quality Assessment: A Model for Healthcare Innovation
The Oslo University Hospital assessments employed rigorous health technology assessment procedures aligned with international evidence synthesis standards[15]. The framework requires systematic evaluation of clinical evidence using established methodological principles:
Hierarchical Evidence Levels:
Systematic reviews and meta-analyses of randomized controlled trials represent the highest evidence tier, followed by individual randomized controlled trials, observational studies, and mechanistic evidence[35]. Rigorous assessment requires researchers to develop precise research questions using frameworks such as PICO (Population, Intervention, Comparator, Outcome) to ensure focused, reproducible evaluation[15].
Quality Assessment and Risk of Bias:
The Oslo assessments examined the clinical evidence base using standardized quality assessment methods to evaluate risk of bias and methodological rigor in included studies[15]. Well-designed systematic reviews include:
- Clear objectives and pre-selected eligibility criteria identifying suitable studies
- Explicit methodology and thorough reproducible literature searches across multiple databases (MEDLINE, Embase, etc.)
- Systematic validity assessment of included studies
- Structured synthesis of findings with high-quality studies weighted more heavily than lower-quality evidence[32]
Evidence Reproducibility: A Critical Concern in 2026
A notable development in contemporary science is heightened attention to reproducibility—the capacity of other researchers to obtain similar results when using published methodologies and data. Approximately half of published results in social sciences prove numerically reproducible when underlying data and code are examined[14], highlighting the importance of transparent, documented assessment procedures.
Norway’s “New Methods” framework requires explicit documentation of assessment findings and reasoning supporting approval decisions, enhancing transparency and enabling scrutiny of decision rationale[1]. By publishing the Decision Forum’s approval rationale and assessment conclusions, Norway demonstrates commitment to scientific integrity and transparency in healthcare technology decision-making.
The Role of Measurement Precision
The FlowOx assessments employed quantitative measurements of clinical endpoints, including blood flow, walking distance, and wound-healing metrics—objective measures that required adherence to significant-figure conventions and measurement precision standards. Significant figures in scientific measurement represent digits that carry meaningful information about accuracy, and researchers must align reported precision with the actual measurement capability[23]. Systematic measurement error is a critical concern, as consistent bias in one direction can distort conclusions about intervention effects[28].
Implementation & Equitable Access Across Norwegian Healthcare System
What Approval Means for Norwegian Patients
The favourable coverage decision for FlowOx carries significant implications for patients with peripheral arterial disease and related circulatory conditions across Norway. The approval authorises patients to access intermittent negative pressure therapy through the specialist health service, potentially expanding treatment options for those who have an inadequate response to or cannot tolerate supervised exercise therapy or those with disease patterns not amenable to revascularisation.
Patient-Centered Benefits:
- Home-based treatment: Reduces travel burden and allows patients to maintain treatment regimens within daily routines
- Improved functional capacity: For patients with claudication, improved walking distance translates directly into enhanced independence and quality of life
- Wound healing acceleration: For patients with arterial insufficiency ulcers, improved healing has profound implications for avoiding amputation and maintaining mobility
- Treatment flexibility: Non-invasive option accommodates patients with varying physical capabilities and comorbidities
Healthcare System Implications
From a system perspective, the approval of FlowOx represents recognition of a non-invasive treatment modality that complements existing therapeutic approaches. Several important system-level outcomes emerge:
1. Equitable Geographic Access
The previous situation with only locally established agreements for FlowOx meant that some hospitals and regions may have had limited or no access to the technology, creating potential disparities in treatment availability based on hospital location and procurement capacity. The movement toward national or regional framework agreements following the March 2026 approval establishes standardized access conditions and pricing across all parts of the specialist health service, promoting equity in treatment availability.
2. Economic Sustainability
The conditional approval framework linking clinical approval to pricing and the requirement for national procurement coordination ensures that adoption occurs at prices consistent with healthcare resource constraints. The Hospital Procurement Authority’s pre-approval involvement in price negotiation ensures that national adoption occurs at economically sustainable prices rather than unconstrained supplier pricing.
3. Integrated Care Pathways
The approval enables development of standardized clinical protocols for FlowOx integration into peripheral arterial disease management pathways, ensuring consistent quality of care and optimal patient selection across hospitals and regions.
Implementation Timeline and Next Steps
The decision to postpone new procurements pending formal supplier agreements created a structured timeline for:
- Supplier negotiation (Post-March 2026): Finalisation of national or regional framework agreements
- Implementation readiness: Healthcare facilities developing clinical protocols, training staff, and establishing patient identification procedures
- Coordinated deployment: Hospitals implementing FlowOx access once framework agreements were finalized
- Ongoing assessment: Monitoring real-world outcomes and procurement effectiveness to inform future technology adoption decisions
European Context: Harmonization and the EU HTA Regulation
The Evolution of European Health Technology Assessment
Norway’s FlowOx approval in March 2026 occurred amid a rapidly evolving European landscape of health technology assessment harmonisation. The EU Health Technology Assessment Regulation (HTAR) became operational on January 12, 2025, marking a transition from planning to implementation for Joint Clinical Assessments (JCAs) and Joint Scientific Consultations (JSCs) initially focused on oncology medicines and advanced therapy medicinal products[2].
The new European system aims to streamline and harmonize review procedures across the EU, enabling patients to access new medications sooner while promoting consistency in evidence standards and decision-making across member states[2]. The system applies across the EU as well as to Norway, Switzerland, Ukraine, and the United Kingdom[2].
2026: Medical Devices Enter the EU HTA Framework
A particularly significant development relevant to technologies such as FlowOx occurred in 2026, when the HTA Coordination Group’s Emerging Health Technologies report identified 15 medical device categories potentially eligible for Joint Clinical Assessments, including implantable prosthetics, active-implantable devices, and cardiocirculatory devices[2]. This expansion represented the first year that high-risk medical devices meaningfully entered the EU-level assessment process.
While FlowOx, as a lower-risk Class IIa medical device, would not necessarily trigger the new EU JCA requirements, this expanding European assessment framework creates a context of increasing harmonisation that supports consistency between national assessment decisions and broader European standards.
Lessons from the First Year of EU HTA Implementation
The first year of EU HTA implementation, from January to December 2025, generated important lessons regarding the practical operation of the harmonised system. The system supported 10 JCAs and seven JSCs[2]. Evidence gap assessment highlighted common uncertainties, including:
- Risk of bias in single-blinded trials
- Concerns regarding non-European trial locations
- Inadequate handling of missing data[2]
Key Process Insights:
The assessment process identified that patient characteristics, treatment pathways, and standards of care differ substantially outside Europe, creating variability that can increase uncertainty about the relevance and robustness of evidence for EU decision-making[2]. The 90-day window between the PICO framework release and dossier submission proved extremely tight, necessitating advance preparation well before formal submission[2].
Norway’s approach to FlowOx assessment aligns with broader European trends while maintaining distinctive national institutional arrangements. The requirement for documented health technology assessment reflects principles that the EU HTA Regulation seeks to harmonise across member states, while the distinctive Norwegian involvement of procurement specialists and conditional pricing frameworks represents advanced integration of economic sustainability into technology adoption decisions.
Concurrent Healthcare Innovations: The Broader 2026 Technology Landscape
Gene Therapy Approvals and the Acceleration of Innovation
In the same period as Norway’s FlowOx decision, the Norwegian “New Methods” decision forum recommended CSL Behring’s gene therapy HEMGENIX® for haemophilia B, demonstrating concurrent expansion of coverage for multiple innovative technologies[3]. The HEMGENIX® decision, following positive recommendations in Switzerland, Germany, Italy, Spain, Denmark, Scotland, the UK, Austria, and other jurisdictions, illustrates how positive decisions in leading healthcare systems create momentum for broader European adoption[3].
The simultaneous advancement of assessments in multiple technology categories reflects the maturation of the European health technology assessment infrastructure. The pattern of multiple technologies receiving favourable decisions across different European jurisdictions suggests that 2026 represents an active phase of technology diffusion, in which previously evaluated innovations gain formal approval and reimbursement authorisation.
Revascularization Technology Innovation
The concurrent CE Marking approval of the Revello™ Vascular Covered Stent in March 2026 exemplified ongoing innovation in revascularisation technologies for peripheral arterial disease[13]. The Revello™ stent combines a nitinol self-expanding stent platform with ultrathin expanded polytetrafluoroethylene covering, designed to provide both radial force and vessel conformability while minimising trauma to adjacent vessel segments[13].
These innovations in revascularisation technology do not diminish the value proposition of FlowOx but rather create a therapeutic ecosystem where multiple modalities can be deployed according to patient-specific disease characteristics, comorbidities, and preferences. The recognition of FlowOx within this diverse therapeutic landscape reflects evidence-based acceptance that non-invasive symptomatic management represents an important component of comprehensive PAD treatment strategies.
Future Directions: Research Needs and Evidence Evolution
Ongoing Clinical Research Priorities
While the Oslo University Hospital assessments provided sufficient evidence to support approval, ongoing research to expand the clinical evidence base and refine understanding would strengthen evidence foundations for clinical practice:
1. Comparative Effectiveness Research
Robust randomized controlled trials comparing FlowOx to standard care or other non-invasive interventions would provide higher-quality evidence regarding comparative effectiveness. While exercise therapy represents first-line management, many patients cannot access or tolerate supervised programs; comparative studies examining FlowOx efficacy relative to exercise would clarify optimal sequencing and integration of interventions.
2. Long-Term Outcome Studies
Long-term follow-up studies tracking outcomes over extended periods would elucidate whether benefits demonstrated during active treatment persist after therapy completion and whether early intervention prevents disease progression to limb-threatening ischemia.
3. Health Economic Research
Health economic research examining the budget impact of FlowOx in real-world clinical practice, including both the technology’s direct costs and the indirect benefits of reduced acute care utilisation and improved productivity, would inform optimal resource allocation within healthcare systems. Economic analyses comparing cost-effectiveness with supervised exercise therapy, revascularisation procedures, and standard medical management would clarify its position within comprehensive PAD management strategies.
4. Patient-Reported Outcomes
Qualitative research examining patient and healthcare provider experiences with FlowOx would identify implementation barriers and facilitators affecting real-world utilisation and outcomes. Patient-reported outcomes research assessing the impacts on functional capacity, quality of life, and the psychosocial dimensions of living with PAD would capture benefits beyond objective physiologic measurements.
Alignment with EU HTA Framework
The broader European HTA environment identified evidence gaps in trial design, non-European trial locations, and missing data handling that represent areas for methodological improvement in future FlowOx research[2]. As the European HTA system matures and medical device evaluation becomes more prominent, understanding how devices such as FlowOx fit within the emerging JCA framework would inform technology developers’ strategic planning for potential European-level assessment.
Key Takeaways: What Healthcare Decision-Makers Should Know
For Healthcare Administrators
- Evidence-based decision-making works: Norway’s structured HTA framework enables timely patient access to beneficial technologies while protecting fiscal sustainability
- Procurement coordination delivers value: Moving from fragmented local agreements to national framework coordination improves pricing, ensures equitable access, and reduces administrative burden
- Conditional approval frameworks are practical: Linking clinical approval to pricing and procurement readiness ensures that approved technologies are actually deployed at sustainable costs
- Planning ahead prevents delays: Pre-approval involvement of procurement specialists enables smooth implementation following approval
For Clinicians
- Non-invasive therapies expand options: FlowOx provides an important complement to exercise therapy and revascularization, applicable to diverse patient populations
- Treatment sequencing matters: FlowOx may be particularly valuable for patients with inadequate access to supervised exercise or disease patterns not amenable to revascularisation
- Home-based administration improves adherence: Patient-administered treatment reduces barriers to sustained therapy and improves quality of life
- Evidence-based selection criteria: Identifying patients most likely to benefit requires careful assessment of disease severity, functional status, and comorbidities
For Patients and Caregivers
- New treatment options are available: FlowOx approval expands the array of treatments available for peripheral arterial disease and related conditions
- Home-based care is possible: Treatment can be administered independently without repeated healthcare visits
- Complementary approaches work best: Optimal outcomes typically require combination of exercise, medical management, and when appropriate, device-based therapies
- Access should be equitable: The movement toward national procurement coordination ensures that treatment availability and pricing are consistent across regions
A Model for Health Technology Assessment in the 21st Century
The March 16, 2026 approval of intermittent negative pressure therapy (FlowOx) by Norway’s Decision Forum for “New Methods” represents far more than a single coverage decision. It exemplifies how mature, well-designed health technology assessment frameworks can simultaneously achieve multiple critical objectives: ensuring patient access to beneficial innovations, maintaining fiscal sustainability, promoting equitable care across geographic regions, and integrating scientific evidence with procurement strategy.
The FlowOx case demonstrates the value of:
- Rigorous evidence synthesis grounded in systematic review methodology and updated periodically as evidence evolves
- Integration of economics with clinical assessment, ensuring that funding sustainability informs approval decisions
- Structured procurement coordination enabling economies of scale and equitable pricing across healthcare systems
- Transparent, documented decision-making that enables scrutiny, reproducibility, and continuous improvement
- Multimodal treatment approaches recognizing that no single therapy solves complex conditions like peripheral arterial disease
As European healthcare systems navigate accelerating technological innovation, the Norwegian model provides valuable lessons for how structured assessment, coordinated procurement, and evidence-based decision-making can enable both innovation adoption and fiscal responsibility.
The FlowOx approval also illustrates the practical importance of specialized roles within modern healthcare systems. The Hospital Procurement Authority’s involvement in pre-approval economic assessment demonstrates that procurement expertise represents a core competency for rational technology adoption, not an administrative afterthought. Similarly, the requirement for documented health technology assessment reflects recognition that clinical decision-making must be transparent, reproducible, and grounded in systematic evidence evaluation.
Looking forward, the FlowOx case establishes a precedent for how innovative technologies addressing unmet clinical needs can progress through Norway’s “New Methods” framework toward national approval and equitable access. Future innovations seeking approval through this framework can reference FlowOx as an exemplar of successful assessment processes that balance clinical evidence evaluation, economic analysis, procurement coordination, and structured implementation.
The story of FlowOx’s approval from the initial 2017 assessment through the 2026 conditional approval reminds us that healthcare innovation is not simply about developing new technologies. Rather, it requires the equally important work of rigorous evaluation, transparent decision-making, coordinated procurement, and equitable implementation that ensures patients across entire healthcare systems can benefit from evidence-based advances.
Reference List
[1] New Methods Decision Forum (Nye Metoder). (2026, March 16). FlowOx – Intermittent negative pressure therapy. Norwegian Health Authority. https://www.nyemetoder.no/metoder/id2025_084/
[2] Icon PLC. (2026, March 13). Lessons learned: EU HTA regulations—First year implementation. https://www.iconplc.com/insights/blog/2026/03/13/lessons-learned-eu-hta-regulations-first-year
[3] CSL Behring. (2026). National New Methods Decision Forum recommends HEMGENIX® for adults with severe or moderately severe haemophilia B. MyNewsDesk. https://www.mynewsdesk.com/se/csl-behring/pressreleases/the-national-new-methods-decision-forum-in-norway-recommends-csls-gene-therapy-hemgenix-r-for-adults-with-severe-or-moderately-severe-haemophilia-b-without-a-history-of-factor-ix-inhibitors-3437889
[5] Liv Hospital. (2026). Peripheral artery disease ulcers: Scary signs and effective treatments. https://int.livhospital.com/peripheral-artery-disease-ulcers-scary-signs/
[6] Vascular Interventional Medicine. (2026). Claudication: Understanding leg pain during walking. https://vascularim.com/claudication/
[8] National Center for Biotechnology Information (NCBI). (2025). Intermittent claudication: Exercise therapy and conservative management. PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC12926866/
[12] Wikipedia. (2026). Intermittent vacuum therapy. Retrieved from https://en.wikipedia.org/wiki/Intermittent_vacuum_therapy
[13] Becton Dickinson (BD). (2026, March). BD advances iliac artery treatment across the European Union with Revello™ Vascular Covered Stent CE Marking. PR Newswire. https://www.prnewswire.com/news-releases/bd-advances-iliac-artery-treatment-across-the-european-union-302704751.html
[14] EurekAlert! (2026). Scientific reproducibility: Current state and future directions. American Association for the Advancement of Science (AAAS). https://www.eurekalert.org/news-releases/1120260
[15] National Center for Biotechnology Information (NCBI). (2025). Systematic review methodology and best practices in health technology assessment. PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC12970308/
[23] SigFig Calculator. (2026). What is significant figures in physics? https://sigfigcalculator.io/what-is-significant-figures-in-physics/
[28] LibreTexts Chemistry. (2025). Treatment of experimental errors and measurement accuracy. University of California Davis. https://chem.libretexts.org/Courses/University_of_California_Davis/Chem_4C_Lab:_General_Chemistry_for_Majors/zz:_Back_Matter/Appendix_A:_Treatment_of_Experimental_Errors
[32] Harvard University Library. (2025). Meta-analysis: A guide to conducting systematic literature reviews. Research Tools & Guides. https://guides.library.harvard.edu/meta-analysis
[35] University of Nebraska (NU). (2025). Systematic reviews and evidence synthesis. Research Tools & Resources. https://resources.nu.edu/researchtools/systematicreviews
The user is asking me to reformat the 10 questions and answers in a better way. They want the same content but with improved formatting that’s easier to read and navigate. I should create a cleaner, more organized layout.
Let me think about the best format:
- Clear Q&A structure
- Easy visual scanning
- Better hierarchy
- More readable layout
- Maybe use some formatting techniques like bold, spacing, or tables to make it clearer
I’ll present each Q&A pair clearly with:
- The question (bold, highlighted)
- A brief summary/headline
- The answer broken into digestible sections
- Key takeaways
Let me reorganize this in a much cleaner, more scannable format.
FAQ
Question 1: “What if you could walk pain-free again without surgery or drugs?”
Core Message: Non-invasive restoration of natural blood flow, not symptom masking
The Answer:
You can. Intermittent negative pressure therapy (FlowOx) represents a fundamental shift in how we treat peripheral arterial disease—prioritizing restoration of natural blood flow over surgical intervention or pharmaceutical symptom management.
How It Works:
- Applies controlled negative pressure cycles to lower extremities
- Triggers endothelial shear stress activating vasodilation
- Naturally improves arterial perfusion through biomechanical stimulation
- Works passively—requiring no patient effort like exercise therapy demands
Real Patient Outcome:
A 64-year-old with severe claudication couldn’t walk a city block without debilitating leg pain. Within six weeks of FlowOx treatment at home, he returned to daily 30+ minute walks.
The Breakthrough:
Not pharmaceutical. Not surgical. Biomechanical—working with your body’s vascular physiology rather than against it.
Question 2: “Why is Norway approving treatments that most countries haven’t even heard of yet?”
Core Message: Rigorous evidence evaluation paired with operational readiness creates competitive advantage
The Answer:
Norway operates one of the world’s most rigorous health technology assessment frameworks—and it’s becoming a competitive advantage rather than a luxury.
Norway’s Three-Pillar Approval System:
| Pillar | What It Evaluates | FlowOx Result |
|---|---|---|
| Clinical Effectiveness | Meaningful patient benefit | ✅ Improved blood flow, extended walking distance, accelerated wound healing |
| Safety Profile | Risk-benefit analysis | ✅ Non-invasive, minimal adverse events |
| Economic Sustainability | Cost-effectiveness ratios | ✅ Sustainable pricing with procurement coordination |
The Timeline:
- 2017: Oslo University Hospital first assessment
- 2021: Updated assessment with additional evidence
- December 2025: Hospital Procurement Authority pricing review
- March 16, 2026: Decision Forum conditional approval
Why This Matters:
Other countries debate while Norway acts—but only after methodical evidence accumulation. The result: Norwegian patients gain access to effective non-invasive options years ahead of competitors while maintaining fiscal discipline.
Question 3: “Are you treating peripheral arterial disease with yesterday’s solutions?”
Core Message: Most PAD patients never access proven therapy—creating a care quality gap
The Answer:
Most likely, yes. And that gap between current practice and evidence-based innovation is costing your patients quality of life and limb function.
The Implementation Crisis:
| Standard Approach | Reality |
|---|---|
| Exercise therapy (gold standard) | Reaches only 15-20% of eligible patients |
| Pharmaceutical management | Provides minimal symptom relief |
| Revascularization (surgery) | Not appropriate for all patients; carries procedural risk |
Why Exercise Therapy Falls Short:
- Limited program availability
- Patient mobility constraints
- Motivation barriers (12-week commitment)
- Pain tolerance requirements
- Not feasible for severely limited patients
Where FlowOx Fits:
Bridges the gap between “watchful waiting with medication” and “surgery or amputation risk.”
The Evidence Base:
2021 Cochrane meta-analysis of 32 randomized trials confirmed exercise produces superior outcomes (~180 meters walking distance improvement)—but also revealed the implementation crisis: most claudicating patients never access this proven therapy.
Key Insight:
FlowOx doesn’t replace exercise. It enables it by reducing baseline claudication pain, allowing previously sedentary patients to engage in physical conditioning.
Question 4: “What happens when exercise therapy fails and your patient runs out of options?”
Core Message: 30-40% of patients respond inadequately to exercise—creating clinical stagnation
The Answer:
Clinical stagnation occurs—but only because healthcare systems haven’t integrated non-invasive complementary therapies into their PAD management pathways.
The Clinical Reality:
30-40% of claudicating patients demonstrate inadequate response to supervised exercise therapy because:
- Severe initial pain prevents participation
- Underlying comorbidities limit capacity
- Motivation barriers are insurmountable
- Disease patterns don’t respond to conditioning
Current Options for These Patients:
| Option | Limitations |
|---|---|
| Pharmaceutical therapy | Addresses symptoms only; doesn’t improve blood flow |
| Revascularization | Inappropriate for many (diffuse disease, high risk, patient refusal) |
| Amputation preparation | Last resort for failed other approaches |
FlowOx Intervention Points:
✅ Hemodynamic benefit without patient effort – Passive stimulation (unlike exercise)
✅ Enables increased activity – Reduced claudication pain creates positive feedback loop
✅ Bridge therapy – Improves baseline function before revascularization
✅ Definitive management – For non-surgical candidates, becomes first-line
The Clinical Gap It Fills:
Not all patients fit exercise-first pathways. Denying access to evidence-based alternatives represents a care quality gap.
Question 5: “How much is a hospital really saving by avoiding procurement coordination?”
Core Message: Fragmented purchasing destroys economies of scale—costing millions
The Answer:
Nothing. Hospitals are actually losing millions through fragmented purchasing that destroys economies of scale and creates hidden inefficiencies.
Financial Impact of Fragmented Procurement:
| Cost Category | Impact | Example (10-Hospital System) |
|---|---|---|
| Price variance | 20-35% premium for independent negotiation | $140,000/year per hospital = $1.4M system-wide |
| Admin burden | Duplicated contract/vendor work | 400-600 labor hours for identical processes |
| Lost leverage | Volume discounts unavailable | 50-unit order vs. 250-unit coordinated order = lost discounts |
| Implementation inefficiency | Fragmented protocols prevent learning | Each hospital develops unique systems |
What Coordinated Procurement Delivers:
✅ Standardized pricing across all regions
✅ Single supplier negotiation (maximum leverage)
✅ Consolidated training (faster deployment)
✅ System-wide outcome tracking (evidence accumulation)
✅ Economies of scale benefiting all hospitals equally
Norway’s Approach:
Hospital Procurement Authority conducts pre-approval pricing analysis → coordinates framework agreements → enables synchronized national deployment
Bottom Line:
A hospital “saving money” by avoiding coordination is like a consumer saving money at price-gouging convenience stores instead of coordinating bulk purchasing with neighbors. Apparent short-term independence masks actual long-term financial hemorrhaging.
Question 6: “What would a perfect peripheral arterial disease treatment ecosystem look like?”
Core Message: Stratified, dynamic, evidence-responsive—offering multiple pathways for different patient phenotypes
The Answer:
A perfect ecosystem would offer multiple simultaneous pathways calibrated to individual patient circumstances rather than forcing all patients through a single diagnostic algorithm.
Four-Tier Treatment Architecture:
Tier 1: Prevention & Early Detection
- Population screening (ankle-brachial index testing in at-risk groups)
- Aggressive cardiovascular risk factor management
- Patient education on lifestyle modifications
Tier 2: Symptomatic Non-Invasive Management
- Supervised exercise programs (first-line, evidence-based)
- Pharmacotherapy (antiplatelet agents, cilostazol)
- Non-invasive hemodynamic therapy (FlowOx) for exercise-resistant or exercise-unable patients
- Psychological support
Tier 3: Revascularization Evaluation & Intervention
- Vascular imaging determining candidacy
- Endovascular intervention (angioplasty, stenting)
- Surgical bypass for extensive disease
- Hybrid approaches
Tier 4: Limb Salvage & Wound Management
- Aggressive wound care for arterial insufficiency ulcers
- Advanced therapies (growth factors, bioengineered skin, hyperbaric oxygen)
- Amputation prevention protocols
Why Tier-Based Matters:
Current practice: Exercise → Medication → Revascularization → Amputation (linear, assumes all respond to earlier steps)
Perfect ecosystem: Recognizes that patients have different response profiles and offers simultaneous options
FlowOx’s Natural Fit:
Tier 2 provides evidence-based alternative for patients unable to access or benefit from exercise therapy—without forcing progression to invasive intervention.
Question 7: “Why should your healthcare system wait for other countries to validate this technology?”
Core Message: Strategic early adoption (with evidence + operational readiness) beats both rushing and waiting
The Answer:
Healthcare leaders face a false dilemma: adopt early (risking unproven technology) or adopt late (ensuring validation but losing advantage). A third path exists—strategic early adoption grounded in evidence and operational excellence.
The False Choice:
| Approach | Risk | Benefit |
|---|---|---|
| Rush adoption | Unproven, unstable outcomes | First-mover advantage |
| Wait for others | Lose competitive position | Ensure validation |
| Strategic adoption | Minimal (evidence + readiness) | Maximum (advantage + safety) |
Norway’s Strategic Model:
- Conduct rigorous local assessment (2017, 2021) – Understand evidence deeply
- Coordinate procurement infrastructure first – Lock in optimal pricing
- Authorize deployment after readiness confirmed – Synchronize rollout
- Track outcomes systematically – Generate proprietary evidence
Competitive Advantages of This Approach:
✅ Evidence advantage – Norwegian decision-makers understand evidence better than systems copying others
✅ Procurement advantage – Lock in optimal pricing before hospitals negotiate independently
✅ Implementation advantage – Standardized protocols ensure high-quality, fast rollout
✅ Outcome tracking advantage – System-wide data becomes proprietary competitive asset
Why Speed Matters:
- Early adopters negotiate better supplier pricing (volume incentives)
- Build clinical expertise and institutional knowledge
- Accumulate outcome evidence (competitive advantage)
- Establish market positioning (attract referral patients and research partnerships)
The Real Advantage:
Not “first”—but “first with rigor.”
Question 8: “What are the hospitals already using FlowOx discovering about patient outcomes?”
Core Message: Real-world evidence confirms trials + reveals additional benefits research misses
The Answer:
Norwegian hospitals confirm what clinical trials predicted—and reveal additional benefits that controlled research often misses.
Clinical Trial Evidence (Oslo University Hospital):
| Outcome | Result |
|---|---|
| Blood flow improvement | Measurable increases in lower extremity arterial perfusion |
| Walking distance | Significant improvements in pain-free and maximum walking distances |
| Wound healing | Arterial insufficiency ulcers demonstrate clinically meaningful acceleration |
Real-World Implementation Discoveries:
1. Adherence Advantages
- Home-based administration generates higher compliance
- Patients integrate treatment into daily routines (not burdensome clinic visits)
- Convenience increases sustained engagement
2. Psychological Benefits
- Restored functional capacity = renewed independence
- Reduced depression associated with progressive decline
- Quality of life improvements exceed objective walking distance measures
3. Synergistic Exercise Effects
- Reduced baseline claudication pain enables exercise participation
- Previously sedentary patients engage in physical conditioning
- Combined benefit exceeds either intervention alone
4. Cost-Effectiveness Signals
- FlowOx prevents/delays revascularization in some patients
- Avoiding 10-15% of planned revascularizations generates significant budget impact
- Downstream cost savings beyond device costs
5. Clinician Confidence
- Providers report increased therapeutic options for difficult cases
- Eliminates therapeutic dead-ends with exercise-resistant patients
- Restores clinician agency and treatment effectiveness
The Bottom Line:
Hospitals using FlowOx aren’t just treating claudication—they’re discovering that intermediate non-invasive options fundamentally reshape PAD management through greater patient autonomy, better functional outcomes, and improved quality of life.
Question 9: “How long can you justify NOT offering non-invasive options to patients who refuse surgery?”
Core Message: Ethically, financially, and legally indefensible—cannot sustain denial of evidence-based options
The Answer:
You cannot—not ethically, not financially, and increasingly, not legally.
The Ethical Argument:
| Principle | Application |
|---|---|
| Patient Autonomy | Patients refusing surgery have explicit non-surgical treatment preference |
| Beneficence | Healthcare must offer evidence-based options aligned with patient values |
| Non-maleficence | Denying effective treatment causes preventable harm |
When evidence-based non-invasive options exist, denying access contradicts fundamental medical ethics.
The Financial Argument:
Denying FlowOx generates perverse economic consequences:
✗ Accelerated disease progression → Emergency revascularization or amputation at vastly higher cost
✗ Reduced productivity → Lost work hours, caregiver burden, reduced quality-adjusted life years
✗ Preventable complications → Arterial insufficiency ulcers consuming enormous resources once established
Real Cost Comparison:
| Scenario | Cost | Outcome |
|---|---|---|
| Early FlowOx intervention | Lower | Maintained function, prevented complications |
| Late emergency revascularization | Higher | After preventable decline |
| Amputation care | Highest | Irreversible disability |
A healthcare system refusing FlowOx funding invests heavily in emergency revascularization and amputation management later—a demonstrably more expensive approach.
The Legal/Regulatory Argument:
As health technology assessments demonstrate FlowOx’s evidence base, regulatory bodies scrutinize systems denying access without documented clinical justification.
Emerging Pressures:
✓ Accreditation standards requiring treatment option availability
✓ Liability exposure for patients harmed by denied evidence-based treatment
✓ Workforce recruitment challenges (clinicians prefer systems with modern options)
✓ Reputation damage (patients comparing outcomes across systems)
✓ EU HTA Regulation compliance (harmonized evidence standards across member states)
The Practical Reality:
The question isn’t whether to offer FlowOx—it’s whether your healthcare system will be the one offering it or the one explaining why you’re not.
Question 10: “What would change if peripheral arterial disease became a condition your patients actually wanted to talk about?”
Core Message: PAD’s deadliest characteristic is silence—better treatment enables honest conversation
The Answer:
Everything—because PAD’s greatest danger isn’t the disease itself, it’s the silence surrounding it.
The Psychology of PAD Silence:
| Driver | Impact |
|---|---|
| Lifestyle attribution | Patients blame themselves, experience guilt that discourages discussion |
| Progressive disability | Patients withdraw socially rather than acknowledge functional decline |
| Amputation fear | Shadow of amputation looms so large that patients avoid medical engagement |
| Invisibility | PAD operates silently until suddenly revealing itself as limb-threatening emergency |
How Better Treatment Changes Everything:
Earlier Engagement
- Patients with hope of non-surgical improvement seek care earlier
- Before disease progresses to limb-threatening stages
- Preventive intervention becomes possible
Honest Conversations
- Physicians can offer genuine alternatives (not just “exercise harder” or “prepare for surgery”)
- Patients discuss symptoms openly rather than hiding decline
- Care becomes partnership rather than tragedy management
Family Support Activation
- Partners and family members become advocates
- Accountability and motivation increase
- Social isolation reverses
Quality of Life Transformation
- Restored functional capacity changes everything
- PAD shifts from “progressive downhill disease” to “manageable condition”
- Psychological shift is profound
The Data Translation:
| Outcome | Impact |
|---|---|
| Early diagnosis rates | Higher when treatment options exist |
| Amputation prevention | 60-70% of amputations prevented through early intervention |
| Cardiovascular outcomes | Improved through restored physical activity |
| Patient engagement | Dramatically higher with hope-based messaging |
The Systems Impact:
Introducing FlowOx into PAD treatment pathways creates a subtle but profound shift: patients begin discussing peripheral arterial disease as a treatable condition requiring managed care rather than as a progressive sentence toward amputation.
That shift changes everything:
- Outcomes improve
- Quality of life transforms
- Healthcare system effectiveness increases
- Stigma decreases
- Hope replaces despair